Kovitz Investment Group Partners LLC Purchases New Stake in Liquidia Technologies, Inc. $LQDA

Key Points

• Kovitz Investment Group Partners LLC has acquired 26,000 shares of Liquidia Technologies, valued at approximately $384,000, as per a recent 13F filing.
• Several hedge funds have significantly increased their stakes in Liquidia Technologies, with Wells Fargo boosting its stake by 69.1% and Invesco by an astounding 2,675.0%.
• Liquidia Technologies reported a revenue increase of 141.5% year-over-year, with quarterly earnings missing estimates at ($0.49) EPS, compared to a consensus estimate of ($0.43).

Kovitz Investment Group Partners LLC purchased a new position in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 26,000 shares of the company's stock, valued at approximately $384,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Whitefort Capital Management LP increased its stake in shares of Liquidia Technologies by 16.8% in the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock worth $23,370,000 after buying an additional 285,220 shares during the last quarter. Vestal Point Capital LP grew its position in Liquidia Technologies by 17.3% in the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock valued at $20,698,000 after buying an additional 260,000 shares in the last quarter. Tang Capital Management LLC raised its position in shares of Liquidia Technologies by 37.5% during the 4th quarter. Tang Capital Management LLC now owns 1,100,000 shares of the company's stock worth $12,936,000 after buying an additional 300,000 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Liquidia Technologies by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after acquiring an additional 674,940 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Liquidia Technologies by 19.5% in the fourth quarter. Northern Trust Corp now owns 589,921 shares of the company's stock valued at $6,937,000 after acquiring an additional 96,381 shares in the last quarter. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. BTIG Research reissued a "buy" rating on shares of Liquidia Technologies in a report on Tuesday, May 27th. Needham & Company LLC boosted their price objective on Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. Bank of America cut their price objective on Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a report on Wednesday, June 11th. HC Wainwright upped their price target on shares of Liquidia Technologies from $29.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, May 28th. Finally, Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $32.11.

Insider Buying and Selling at Liquidia Technologies

In other news, CEO Roger Jeffs sold 20,252 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $289,198.56. Following the sale, the chief executive officer owned 1,038,560 shares in the company, valued at approximately $14,830,636.80. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Kaseta sold 30,000 shares of Liquidia Technologies stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $20.00, for a total transaction of $600,000.00. Following the sale, the chief financial officer directly owned 376,412 shares of the company's stock, valued at $7,528,240. This represents a 7.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 90,277 shares of company stock worth $1,469,392 over the last 90 days. Company insiders own 26.50% of the company's stock.

Liquidia Technologies Stock Performance

LQDA stock traded down $0.46 during mid-day trading on Friday, reaching $26.84. 2,601,589 shares of the stock traded hands, compared to its average volume of 3,258,115. The firm has a market capitalization of $2.31 billion, a PE ratio of -15.79 and a beta of 0.14. The business has a 50-day moving average of $17.51 and a two-hundred day moving average of $15.96. The company has a quick ratio of 2.41, a current ratio of 2.49 and a debt-to-equity ratio of 9.84. Liquidia Technologies, Inc. has a 52 week low of $8.75 and a 52 week high of $28.00.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). The company had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The firm's quarterly revenue was up 141.5% compared to the same quarter last year. As a group, equities analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).